An observational study in Stable Coronary Artery Disease and Acute Coronary Syndromes, sponsored by Ceric Sàrl. Recruiting at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-23.
Sponsored by Ceric Sàrl · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 85 studies in Acute Coronary Syndrome with a site in Spain — 13 open to participants now, 16 under way, 1 of them phase 3. Acute Coronary Syndrome · Spain.
Among the 85 studies in Acute Coronary Syndrome with a site in Spain, this one is the 16th largest by planned enrollment of the 25 observational ones that give a count, is one of 4 that started in 2026, is one of 25 observational ones, reaches primary completion later than 12 of the 15 other live ones, and was the 80th registered.
1,491 studies on the registry are indexed under Acute Coronary Syndrome; 272 are open to participants now.
Browse Acute Coronary Syndrome studies →13 of the 85 studies in Acute Coronary Syndrome with a site in Spain are open now. Recruiting first, the newest first:
Kristian Rivera · Sites in Spain, Mexico
Ages 18+
Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz · Sites in Spain, Ireland, Latvia and 2 more countries
Ages 18+
Fundación para la Investigación del Hospital Clínico de Valencia · Sites in Spain
Ages 65+
Abcentra · Sites in Spain, United States, Czechia and 6 more countries
Ages 18+
Spanish Society of Cardiology · Sites in Spain
Ages 18+
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 195 Acute Coronary Syndrome studies recruiting now, 144 (74%) set no upper age limit and 19 (10%) stop at 75 or younger; 15 take children under 18; 15 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
85 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 4 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 500 is close to the median of 500 across 590 observational studies indexed under Acute Coronary Syndrome.
Median enrollment 588 across the 60 interventional studies, 900 across the 25 observational. Of the 58 that completed or were terminated, 20 (34%) have results posted.
This tab as a report to print or save as PDF → With an account.
33 of 85 have an industry lead sponsor. The 10 most frequent:
Ceric Sàrl is the lead sponsor of 17 studies on the registry; 11 are open to participants now.
Ceric Sàrl has 3 studies filed under Acute Coronary Syndrome — fewer than ten, so there is no comparison to draw.
5 of the studies in Acute Coronary Syndrome with a site in Spain that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07102628Phase 3Novartis PharmaceuticalsEvaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronary Syndromes | 2027-01-16 |
| NCT06736665Spanish Society of CardiologyOrbital Atherectomy vs Intravascular Lithotripsy for the Treatment of Calcified Coronary Nodules (ORBIT-SHOCK). | 2026-12 |
| NCT06927739AbcentraFocused Orticumab Research for Treating Inflammation in Coronary Arteries | 2027-02-08 |
| NCT07091682Biotronik AGSafety and Clinical Performance of the Freesolve Resorbable Magnesium Scaffold System in the Treatment of Subjects With Long de Novo Lesions | 2027-06 |
| NCT07038265Institut d'Investigació Biomèdica de BellvitgePatient-centered Personalized Cardiac Rehabilitation in Post Acute Coronary Syndrome (BREAK-trial) | 2027-11 |
Add all 5 to your calendar (.ics) → With an account.
Among the 85 studies in Acute Coronary Syndrome with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is a prospective, investigator-initiated, multi-center, single arm, observational registry of performance of Excimer Laser Coronary Atherectomy (ELCA) in standard use cases of percutaneous coronary intervention (PCI).
The primary objective of the CLARIT study is to assess the Safety and Efficacy of ELCA in recognized indications for the device at Index PCI and during the in-hospital stay. The secondary objectives includes the safety and efficacy of ELCA at 30 days and 1 year, as well as the procedural characteristics for the assessment of the learning curve and impact on the catheter lab workflow.
500 patients will be included in 20 sites accorss 8 countries in Europe, United Kingdom and India. The patients included in the study according to eligibility criteria will be followed up one year. The total study duration is 3 years, including 2 years of recruitment.
The follow-up/visit windows include the screening/baseline period, on the day of procedure, discharge; 1 month and 1 year follow-up. The ELCA is to be used following Instruction for uses and follow-up as per hospital standard of care.
Patients with stable coronary artery disease or acute coronary syndromes who will be treated with excimer laser coronary atherectomy (ELCA)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subjects will be included if all the following criteria are met:
Patients with stable coronary artery disease or acute coronary syndromes with de-novo or intra-stent restenosis (ISR) coronary lesions suitable to be treated with ELCA
Mandated use of ICI:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ELCA treat a significant coronary stenosis or recanalize occluded coronary arteries using UV during percutaneous coronary intervention.
Procedural success during index PCI
The primary endpoint of efficacy is procedural Success during index PCI:, which is a combined endpoint of these following events: * Angiographic success defined as residual stenosis \<30% in two orthogonal projections after lesion treatment with ELCA destination therapy with DES or DCB * TIMI 3 flow and absence of ELCA related complications during the procedure * Intra-Coronary Imaging success defined as final MSA \> 5.5mm2 IVUS or 4.5mm2 OCT with \> 80% stent expansion - site reported
Time frame: During Procedure
Freedom from in hospital Major Adverse Cardiovascular Events
The primary endpoint of safety is freedom from in-hospital Major Adverse Cardiovascular Events (MACE), including : cardiac death, target vessel myocardial infarction (TVMI), urgent repeat target vessel revascularization (TVR) with either PCI or CABG, and Stroke.
Time frame: Periprocedural
Composite endpoint of one of events reported
The secondary endpoint is a composite endpoint of one of these event : Major Adverse Cardiovascular Events (MACE) (including cardiac death, target vessel revascularization, myocardial infarction, target vessel myocardial infarction (TVMI), unplanned hospitalization of unstable angina).
Time frame: 30 days and 1 year
Success of revascularization: Freedom from Target lesion failure (TLF) events and ICI assessed stent optimization
This is defined by MSA stent expansion,stent apposition, full lesion coverage with \< 50% plaque burden at proximal and distal references with TIMI 3 flow, no significant edge dissection
Time frame: 30 days and 1 year
Procedural Characteristic- Cost
Procedural costs (devices used)
Time frame: During procedure
Procedural Characteristic- Device success based on maximum fluence
Device Success based on maximum fluence
Time frame: During procedure
Procedural Characteristic- Fluoroscopy Time
Fluoroscopy time
Time frame: During procedure
Procedural Characteristic- Contrast Volume
Contrast Volume
Time frame: During procedure
Procedural characteristic- Device success based on repetition rate
Device Success based on repetition rate
Time frame: During procedure
Procedural characteristic- Device success based on pulses number
Device Success based on number of pulses
Time frame: During procedure
Procedural characteristic- Device success based on lasing duration
Device Success in relation to the duration of lasing
Time frame: During Procedure
Procedural characteristic- Device success based on laser trains number
Device Success in relation to the number of laser trains
Time frame: During procedure
Procedural characteristic- Catheter access
Catheter access : radial or femoral
Time frame: During Procedure
Requirement of hemodynamic support
composite of need for pharmacological or mechanical hemodynamic support
Time frame: During procedure
Marker of the learning curve associated with ELCA- Total procedure time
The total time of the procedure
Time frame: During procedure
Marker of the learning curve associated with ELCA- Intra-procedural interval from ELCA decision to post-ELCA intracoronary imaging
The time between the decision for ELCA to the uses of Intracoronary imaging after ELCA.
Time frame: During procedure
Marker of the learning curve associated with ELCA- Number of ECLA trains
The number of ELCA trains, including the number of pulses, settings performed by the clinician.
Time frame: During procedure
Marker of the learning curve associated with ELCA- Milieu type used during lasing
The type of milieu used during lasing (blood, saline or contrast)
Time frame: During procedure
Impact on catheter lab workflow- Lesion preparation strategy
The change in lesion preparation strategy compared to the operator's initial upfront declared strategy (uses of IVL, specialty balloons or other atherectomy device alongside ELCA).
Time frame: During procedure
Impact on catheter lab workflow- Stent Strategy
The change of stent strategy (after ELCA and subsequent ICI) compared to the operator's initial upfront declared strategy.
Time frame: During procedure
Impact on catheter lab workflow- Procedural duration
Procedural duration for decision of ELCA to passage of Intracoronary imaging or ballon
Time frame: During procedure
Intracoronary imaging analysis by the site- Calcium morphology
Calcium morphology (concentric, eccentric or nodular) reported by the site.
Time frame: During procedure
Intracoronary imaging analysis by the site- Depth of lesion calcification
Depth of lesion calcification reported by the site.
Time frame: During procedure
Intracoronary imaging analysis by the site- Lesion calcification length
Length of lesion calcification reported by the site
Time frame: During procedure
Intracoronary imaging analysis by the CoreLab
calcium burden (%)
Time frame: During procedure
Intracoronary imaging analysis by the CoreLab
calcium depth (mm)
Time frame: During Procedure
Intracoronary imaging analysis by the CoreLab
impact of OAS and other devices on calcium
Time frame: During procedure
Intracoronary imaging analysis by the CoreLab
minimal stent area (mm²)
Time frame: during procedure
Intracoronary imaging analysis by the CoreLab
stent expansion (%)
Time frame: During Procedure
Intracoronary imaging analysis by the CoreLab
presence of edge dissection
Time frame: During Procedure
Intracoronary imaging analysis by the CoreLab
presence of stent malposition
Time frame: During procedure
Intracoronary imaging analysis by the CoreLab
maximal eccentricity index
Time frame: During procedure
Plan to share: Undecided
No publications or documents are linked to this record.
Started Jul 2026 (actual). Primary completion is estimated for Jul 2028, 24 months after the start.
Of 34 industry-sponsored observational studies under Acute Coronary Syndrome, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 42. This study's planned 24 months is below that.
Counting every sponsor, half of 277 studies reached it within 35 months; a quarter within 18 and three quarters within 68.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.